To Evaluate an MRI-based Optimized Prostate Cancer Diagnostic Pathway Powered by Artificial Intelligence - Trial NCT06360523
Access comprehensive clinical trial information for NCT06360523 through Pure Global AI's free database. This phase not specified trial is sponsored by Chinese University of Hong Kong and is currently Not yet recruiting. The study focuses on Prostate Cancer. Target enrollment is 102 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chinese University of Hong Kong
Timeline & Enrollment
N/A
May 01, 2024
Jul 20, 2025
Primary Outcome
Prostate Cancer detection rate of ISUP grade group ≥2
Summary
It is a prospective paired-cohort study for diagnostic test evaluation. The study aim to
 determine the accuracy of AI review and investigate whether AI review could detect MRI
 visible significant cancer as effective as radiologist review. MRI image of about 102 men
 recommended for biopsy will be reviewed by an AI model and an experienced radiologist,
 respectively. AI review (index) and radiologist review (standard) will be blinded to each
 other, while biopsy urologists will be well-informed of the findings of both AI review and
 radiologist review and make personalized biopsy plan by combining both findings. The
 pathological results of MRI-ultrasound fusion biopsy (reference) will serve as the gold
 standard to assess the diagnostic accuracy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06360523
Non-Device Trial